Tuesday, 07 Apr 2020

You are here

Ideal Outcomes are Seldom Achieved in Gout

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout. 

The GRESGO (gout) cohort of 500 patients compared outcomes in 221 with severe gout (44%) and 279 with non-severe gout (56%). Patients were followed at 6-month intervals. 

Ssevere gout patients were younger, with lower educational and socioeconomic status, longer disease duration, more absenteeism, more hypertension and chronic renal failure, more affected joints and tophi, and more activity limitations. Predictors of severe gout were disease duration (p=0.008) and gout flares (p=0.055).

While there were no significant differences between these groups in achieving an sUA U 6 mg/dL or 5 mg/dL (non-severe and severe gout, respectively), target urate < 6 mg/dL was achieved in 50-70% of the patients followed for 3-5 years and less than 50% of patients achieved TU < 5mg/dL during 5 years of follow-up.

Remission (no flares, SUA < 6.0, Pain < 2.0; no tophi) was achieved less often: 9.1% at year 1; 30% at year 2; 28% at year 3 and 28% after 5 years. None of the patients with severe gout achieved remission.

Patients with severe gout were unlikely to achieve both target sUA and remission. Hence, there exists many obstacles to achieving a target sUA and remission in gout. include poor medication adherence, persistent tophi and loss to follow-up.

These findings are in line with multiple studies showing that the target sUA is only achieved in 30-40% of gout patients.  However, many recent gout management studies have shown far better (80-80%) rates of remission and target sUA < 6.0 when patients are managed by nurses or pharmacists using a treat to target protocol, usually at more frequent intervals (every1-2 mos.).

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.